Astellas Divests Prosidion’s DPP-IV Inhibitor Patent Assets to Royalty Pharma
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 7 (Table of Contents)
Published: 12 Jul-2011
DOI: 10.3833/pdr.v2011.i7.1493 ISSN: 1756-7874
Section: Royalties
Fulltext:
Abstract
Japan’s Astellas Pharma has sold off the patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes held by its Prosidion subsidiary for US$609 M in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS